Benzinga | Jan 11, 2021 05:57AM EST

BTIG Initiates Coverage On BioAtla with Buy Rating, Announces Price Target of $47

BTIG analyst Thomas Shrader initiates coverage on BioAtla (NASDAQ:BCAB) with a Buy rating and announces Price Target of $47.